CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million

Reuters

Feb 13

CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million

CVRx Inc. reported its financial and operating results for the fourth quarter (Q4) and full year (FY) 2025. Total revenue for Q4 2025 was USD 16.0 million, reflecting a 4% increase. U.S. revenue for the quarter reached USD 14.9 million, also up 4%. For FY 2025, total revenue amounted to USD 56.7 million, an increase of 10%. The company reported a net loss per share, basic and diluted, of USD 0.46 for Q4 2025. Cash and cash equivalents as of December 31, 2025, totaled USD 75.71 million. Operational highlights for the period include growth in the number of active implanting centers in the U.S. to 252, up from 223 in the prior year. CVRx also initiated the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. Looking ahead, CVRx expects full year 2026 total revenue to be between USD 63.0 million and USD 67.0 million, gross margin between 84% and 86%, and operating expenses between USD 103.0 million and USD 107.0 million. For the first quarter (Q1) of 2026, the company anticipates total revenue between USD 13.7 million and USD 14.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9653213) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611335970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611335970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611335970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611335970","market":"fut","top_or_hot":-1,"title":"CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CVRx Inc. reported its financial and operating results for the fourth quarter (Q4) and full year (FY) 2025. Total revenue for Q4 2025 was USD 16.0 million, reflecting a 4% increase. U.S. revenue for the quarter reached USD 14.9 million, also up 4%. For FY 2025, total revenue amounted to USD 56.7 million, an increase of 10%. The company reported a net loss per share, basic and diluted, of USD 0.46 for Q4 2025. Cash and cash equivalents as of December 31, 2025, totaled USD 75.71 million. Operational highlights for the period include growth in the number of active implanting centers in the U.S. to 252, up from 223 in the prior year. CVRx also initiated the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. Looking ahead, CVRx expects full year 2026 total revenue to be between USD 63.0 million and USD 67.0 million, gross margin between 84% and 86%, and operating expenses between USD 103.0 million and USD 107.0 million. For the first quarter (Q1) of 2026, the company anticipates total revenue between USD 13.7 million and USD 14.7 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9653213) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Inc. FY2025 revenue rises 10% to USD 56.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CVRx Inc. reported its financial and operating results for the fourth quarter (Q4) and full year (FY) 2025. Total revenue for Q4 2025 was USD 16.0 million, reflecting a 4% increase. U.S. revenue for the quarter reached USD 14.9 million, also up 4%. For FY 2025, total revenue amounted to USD 56.7 million, an increase of 10%. The company reported a net loss per share, basic and diluted, of USD 0.46 for Q4 2025. Cash and cash equivalents as of December 31, 2025, totaled USD 75.71 million. Operational highlights for the period include growth in the number of active implanting centers in the U.S. to 252, up from 223 in the prior year. CVRx also initiated the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. Looking ahead, CVRx expects full year 2026 total revenue to be between USD 63.0 million and USD 67.0 million, gross margin between 84% and 86%, and operating expenses between USD 103.0 million and USD 107.0 million. For the first quarter (Q1) of 2026, the company anticipates total revenue between USD 13.7 million and USD 14.7 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9653213) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL6jF0RL:1","article_id":"2611335970","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611335970","pubTimestamp":1770930421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CVRx Inc. reported its financial and operating results for the fourth quarter  and full year  2025. Total revenue for Q4 2025 was USD 16.0 million, reflecting a 4% increase. U.S. revenue for the quarter reached USD 14.9 million, also up 4%. For FY 2025, total revenue amounted to USD 56.7 million, an increase of 10%. The company reported a net loss per share, basic and diluted, of USD 0.46 for Q4 2025. Cash and cash equivalents as of December 31, 2025, totaled USD 75.71 million. Operational highlights for the period include growth in the number of active implanting centers in the U.S. to 252, up from 223 in the prior year. CVRx also initiated the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. Looking ahead, CVRx expects full year 2026 total revenue to be between USD 63.0 million and USD 67.0 million, gross margin between 84% and 86%, and operating expenses between USD 103.0 million and USD 107.0 million. For the first quarter  of 2026, the company antic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4539":"次新股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","CVRX":"CVRx, Inc.","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"CVRX Inc.2025财年收入增长10%至5670万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CVRX":0.9},"content_text":"CVRx Inc. FY2025 revenue rises 10% to USD 56.7 million\n    \n\n        CVRx Inc. reported its financial and operating results for the fourth quarter (Q4) and full year (FY) 2025. Total revenue for Q4 2025 was USD 16.0 million, reflecting a 4% increase. U.S. revenue for the quarter reached USD 14.9 million, also up 4%. For FY 2025, total revenue amounted to USD 56.7 million, an increase of 10%. The company reported a net loss per share, basic and diluted, of USD 0.46 for Q4 2025. Cash and cash equivalents as of December 31, 2025, totaled USD 75.71 million. Operational highlights for the period include growth in the number of active implanting centers in the U.S. to 252, up from 223 in the prior year. CVRx also initiated the BENEFIT-HF trial, with first enrollments expected in the second quarter of 2026. Looking ahead, CVRx expects full year 2026 total revenue to be between USD 63.0 million and USD 67.0 million, gross margin between 84% and 86%, and operating expenses between USD 103.0 million and USD 107.0 million. For the first quarter (Q1) of 2026, the company anticipates total revenue between USD 13.7 million and USD 14.7 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9653213) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}